{"id":"116395003d41","type":"article","url":"https://hartvaat.nl/2016/07/19/sacubitril-valsartan-en-30-daagse-heropname-na-hartfalenhospitalisatie/","title":"Sacubitril/valsartan en 30-daagse heropname na hartfalenhospitalisatie","title_en":"Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["acuut-hartfalen","answer-hf","sacubitril-valsartan"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2016.04.047","source_url":"https://doi.org/10.1016/j.jacc.2016.04.047","authors":["Akshay S Desai","Brian L Claggett","Milton Packer","Michael R Zile","Jean L Rouleau","Karl Swedberg","Victor Shi","Martin Lefkowitz","Randall Starling","John Teerlink","John J V McMurray","Scott D Solomon"],"significance":7,"published":"2016-07-19","source_date":"2016-07-19","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/arni-sacubitril-valsartan/"],"congress":"","summary_en":"This analysis showed that sacubitril-valsartan reduces 30-day heart failure readmission rates after hospitalization, addressing a high-priority quality metric in heart failure care.","created":"2026-07-03T10:26:13Z","updated":"2026-07-03T18:38:26Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van het effect van sacubitril/valsartan (LCZ696) op 30-daagse heropnames na een hartfalenhospitalisatie. Klinisch relevant voor het acute-naar-chronisch hartfalentraject.","abstract_original":"BACKGROUND: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. OBJECTIVES: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital readmission at 30-days following HF hospitalization compared with enalapril. METHODS: We assessed the risk of 30-day readmission for any cause following investigator-reported hospitalizations for HF in the PARADIGM-HF trial, which randomized 8,399 participants with HF and reduced ejection fraction to treatment with LCZ696 or enalapril. RESULTS: Accounting for multiple hospitalizations per patient, there were 2,383 investigator-reported HF hospitalizations, of which 1,076 (45.2%) occurred in subjects assigned to LCZ696 and 1,307 (54.8%) occurred in subjects assigned to enalapril. Rates of readmission for any cause at 30 days were 17.8% in LCZ696-assigned subjects and 21.0% in enalapril-assigned subjects (odds ratio: 0.74; 95% confidence interval: 0.56 to 0.97; p = 0.031). Rates of readmission for HF at 30-days were also lower in subjects assigned to LCZ696 (9.7% vs. 13.4%; odds ratio: 0.62; 95% confidence interval: 0.45 to 0.87; p = 0.006). The reduction in both all-cause and HF readmissions with LCZ696 was maintained when the time window from discharge was extended to 60 days and in sensitivity analyses restricted to adjudicated HF hospitalizations. CONCLUSIONS: Compared with enalapril, treatment with LCZ696 reduces 30-day readmissions for any cause following discharge from HF hospitalization."}